Cloning of the genes for non-medullary thyroid cancer: Methods and advances

Archive of Oncology

Volumn 14, Issue 1-2, 2006, Pages 30-34

  Stankov, Karmen ^a   Romeo, Giovanni ^b  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cloning, Molecular; Genes, Tumor Supressor; Genetic Predisposition to Disease; Oncogenes; Thyroid Neoplasms

Indexed keywords

CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; DISEASE ASSOCIATION; GENE IDENTIFICATION; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; MALIGNANT TRANSFORMATION; MOLECULAR CLONING; REVIEW; THYROID CANCER;

EID: 33748436540     PISSN: 03547310     EISSN: None     Source Type: Journal    
DOI: 10.2298/AOO0602030S     Document Type: Review

References (38)

1. Alsanea O, Clark OH. Familial thyroid cancer. Curr Opin Oncol 2001;13:44-51.
2. Fagin JA. Editorial: Familial nonmedullary thyroid carcinoma - the case for genetic susceptibility. J Clin Endocrinol Metab 1997;82:342-4.
3. Gemmill RM, West JD, Boldog F, Tanaka N, Robinson LJ, Smith DI, et al. The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8. Proc Natl Acad Sci USA 1998;95(16):9572-7.
4. Herrera L, Kakati S, Gibas L, Pietrzak E, Sandberg AA. Gardner syndrome in a man with an interstitial deletion of 5q. Am J Med Genet 1986;25(3):473-6.
5. Hemminki A, Tomlinson I, Markie D, Jarvinen H, Sistonen P, Bjorkqvist AM, et al. Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat Genet 1997;15(1):87-90.
6. Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998;18(1):38-43.
7. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998;391(6663):184-7.
8. Kainu T, Juo SH, Desper R, Schaffer AA, Gillanders E, Rozenblum E, et al. Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci USA 2000;97(17):9603-8.
9. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921.
10. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001;291:1304-51.
11. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997;16:64-7.
12. Rodien P, Bourdelot A, Savagner F. Update in thyroid endocrinology. EMC-Endocrinologie 2005;2:39-49.
13. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B. BRAF mutation in papillary thyriod carcinoma. J Natl Cancer Inst 2003;95:625-7.
14. Leenhardt L, Ménégaux F, Franc B, Hoang C, Salem S, Bernier MO, et al. Thyroid cancer. EMC-Endocrinologie 2005;2:1-38.
15. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science 2000;289:1357-60.
16. Gregory Powell J, Wang X, Allard BL, Sahin M, Wang XL, Hay ID, et al. The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition. Oncogene 2004;23:3634-41.
17. Cheung L, Messina M, Gill A, Clarkson A, Learoyd D, Delbridge L, et al. Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 2003;88:354-7.
18. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003;88:2318-26.
19. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 2002;26:1016-23.
20. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda Rogounovitch TI. Clinical implication of hot spot BRAF mutation, V599E, in papilary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393-7.
21. Malchoff CD, Sarfarazi M, Tendler B, Forouhar F, Whalen G, Joshi V, Arnold A, Malchoff DM. Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab 2000;85:1758-64.
22. Stankov K, Romeo G. Oxyphilic carcinoma of the thyroid. Arch Oncol 2003;11:13-21
23. Tallini G, Hsueh A, Liu S, Garcia-Rostan G, Speicher MR, Ward DC. Frequent chromosomal DNA unbalance in thyroid oncocytic (Hürthle cell) neoplasms detected by comparative genomic hybridization. Lab Invest 1999;79:547-55.
24. Volante M, Papotti M, Gugliotta P, Migheli A, Bussolati G. Extensive DNA fragmentation in oxyphilic cell lesions of the thyroid. J Histochem Cytochem 2001;49:1003-11.
25. Máximo V, Sores P, Rocha AS, Sobrinho-Simöes M. The common deletion of mitochondrial DNA is found in goiters and thyroid tumors with and without oxyphil cell change. Ultrastruct Pathol 1998;22:271-3.
26. Máximo V, Sobrinho-Simöes M. Hürthle cell tumours of the thyroid. A review with emphasis on mitochondrial abnormalities with clinical relevance. Virchows Arch 2000;437:107-15.
27. Volante M, Croce S, Pecchioni C, Papotti M. E2F-1 transcription factor is overexpressed in oxyphilic thyroid tumors. Mod Pathol 2002;15:1038-43.
28. Stankov K, Landi S, Gioia-Patricola L, Bonora E, Volante M, Papotti M, Romeo G. GSTT1 and M1 polymorphisms in Hürthle thyroid cancer patients. Cancer Letters 2006; in press.
29. Ginsberg D. E2F1 pathways to apoptosis. FEBS Lett 2002;529:122-5.
30. Hoos A, Stojadinovic A, Singh B, Dudas ME, Leung DH, Shaha AR, et al. Clinical significance of molecular expression profiles of Hurthle cell tumors of the thyroid gland analyzed via tissue microarrays. Am J Pathol 2002;160:175-83.
31. Müller-Höcker J. Expression of bcl-2, Bax and Fas in oxyphil cells of Hashimoto thyroiditis. Virchows Arch 2000;436:602-7.
32. Lesueur F, Stark M, Tocco T, Ayadi H, Delisle MJ, Goldgar DE, Schlumberger M, Romeo G, Canzian F. Genetic heterogeneity in Familial Non-Medullary thyroic carcinoma: Exclusion of RET, MNG1 and TCO in 56 families. J Clin Endocrinol Metab 1999;84:2157-62.
33. Canzian F, Amati P, Harach HR, Kraimps JL, Lesueur F, Barbier J, et al. A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am J Hum Genet 1998;63:1743-8.
34. Stankov K, Pastore A, Toschi L, McKay J, Lesueur F, Kraimps JL, et al. Allelic loss on chromosomes 2q21 and 19p13.2 in oxyphilic thyroid tumors. Int J Cancer 2004;111:463-7.
35. Stankov K. Functional and genetic study of thyroid carcinoma with cell oxyphilia (disertation). Novi Sad: Medical Faculty Novi Sad; 2004.
36. Stankov K, Biondi A, D'Aurelio M, Gasparre G, Falasca A, Romeo G, et al. Mitochondrial activities of cell line derived from thyroid Hürthle cell tumors. Thyroid 2006; in press.
37. McKay JD, Lesueur F, Jonard L, Pastore A, Williamson J, Hoffman L, et al. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet 2001;69:440-6.
38. McKay JD, Thompson D, Lesueur F, Stankov K, Pastore A, Watfah C, et al. Evidence for interaction between the TCO and NMTC1 loci in familial non-medullary thyroid cancer. J Mol Genet 2004;41:407-12.